Last updated: April 25, 2026
Who supplies guanfacine hydrochloride to the pharmaceutical supply chain?
Guanfacine hydrochloride is an established, off-patent small-molecule active pharmaceutical ingredient (API) used primarily in extended-release (ER) formulations (notably for pediatric ADHD and hypertension). Supplier coverage depends on whether you want (1) API manufacture, (2) finished-dose supply, or (3) contract manufacturing (CDMO) for tablets/capsules using sourced API.
Bottom line: the market has multiple qualified sources for guanfacine hydrochloride API and for finished products, with supply split between API specialists and large generics/CDMOs that also support combination and ER solid-dose manufacturing.
What forms of guanfacine do suppliers provide?
Most commercial supply focuses on:
- Guanfacine hydrochloride API (active pharmaceutical ingredient) for solid oral products
- Finished-dose solid oral products (tablets) using guanfacine hydrochloride, including ER variants
Common drug form nomenclature you will see across catalogs:
- “guanfacine hydrochloride” (API)
- “guanfacine ER tablets” (finished dose; the API is typically guanfacine HCl)
- Strength labeling varies by jurisdiction (for ER: commonly 1 mg, 2 mg, 3 mg, 4 mg)
Which supplier categories exist for guanfacine hydrochloride?
- API manufacturers (make and sell guanfacine hydrochloride under their own sites and quality systems)
- API distributors/traders (source from manufacturers and resell, often for smaller volume buyers)
- CDMOs for solid oral (formulate and manufacture tablets using supplied guanfacine HCl API)
- Finished-dose generic manufacturers (sell finished guanfacine ER products via national tender and wholesaler channels)
Which countries dominate guanfacine hydrochloride supply?
The supply base for off-patent, small-molecule APIs is concentrated in:
- China
- India
- EU (smaller share for direct API supply, higher share for finished-dose manufacturing)
This pattern matches the broader sourcing structure for mature, commodity-style APIs, where contract manufacturing scale and cost positioning are decisive.
How do you identify qualified guanfacine hydrochloride suppliers?
Qualification typically relies on:
- API manufacturer GMP status for the relevant regulatory regime (FDA, EMA, MHRA, etc.)
- DMF/ASMF coverage (for US: Drug Master File; for EU: ASMF) if the supplier is intended for generics registration packages
- CoA/analytical system alignment (assay, related substances, particle size where relevant, residual solvents, polymorph control where applicable)
For buyers in generics or CDMO contexts, the practical workflow is:
- Confirm API site GMP and documentation package (DMF/ASMF or equivalent)
- Confirm intended drug product linkage to ER tablet process needs
- Run supplier change control and testing plan for identity, impurities, and dissolution consistency
What does supplier documentation usually include for guanfacine hydrochloride?
Typical dossier elements supplied to customers (directly or via regulatory submissions) include:
- Certificate of Analysis (CoA) per batch
- Specification: assay range, water content/LOD, residual solvents, related substances (impurity profile)
- Analytical methods (HPLC/UV-based assays are standard for guanfacine HCl)
- Stability data (long-term and accelerated storage conditions)
- GMP compliance and traceability statements
Where do suppliers typically list guanfacine hydrochloride?
Commercially, guanfacine hydrochloride is sourced through three primary discovery channels:
- API manufacturer websites and catalog listings
- Distributor networks (API marketplaces and procurement platforms)
- Regulatory dossier ecosystems where DMF/ASMF holders are referenced for registration support
If you are evaluating suppliers for clinical or commercial drug substance supply, the key is not catalog presence but regulatory-ready documentation tied to the API manufacturing site.
Key supply reality for guanfacine hydrochloride (what matters operationally)
For ER solid dose programs, purchasing decisions hinge on:
- Impurity profile consistency across lots
- Solvent and water control aligned to tablet formulation process
- Particle/process consistency that drives downstream compression and dissolution behavior in ER matrices
- Supply reliability for long-tenor commercial demand
These are the levers that reduce revalidation risk at formulation and scale-up.
Key Takeaways
- Guanfacine hydrochloride supply is split across API manufacturers, distributors, CDMOs, and finished-dose generic manufacturers, with sourcing concentrated in China and India.
- For high-stakes procurement, qualification depends on GMP status by site and regulatory documentation (DMF/ASMF where applicable), not only product listing.
- Operational success for ER tablet programs depends on impurity and batch-to-batch specification control tied to formulation and dissolution performance.
FAQs
1) Is guanfacine hydrochloride widely available as an API?
Yes. It is an established API with multiple supplier categories and geographic manufacturing coverage, with China and India forming the bulk of API sourcing.
2) Do suppliers sell guanfacine hydrochloride only as API?
Many do. A parallel stream is finished-dose supply, where manufacturers buy guanfacine HCl and make ER tablets under their own manufacturing authorizations.
3) What documentation matters most when selecting an API supplier?
Site GMP alignment and a customer-facing regulatory package suitable for your filing strategy, typically including CoA, specifications, and the ability to support DMF/ASMF-based registration needs where relevant.
4) What specs drive ER tablet performance risk?
Related substances/impurity profile, assay consistency, residual solvents/water, and any material attributes affecting dissolution and compression behavior.
5) How do buyers typically validate a new guanfacine HCl supplier?
They do an incoming quality verification against established specifications, then run compatibility and formulation/processing performance checks consistent with ER manufacturing requirements.
References
[1] FDA. “Drug Master Files (DMFs).” FDA website. https://www.fda.gov/drugs/drug-master-files-dmf
[2] European Medicines Agency. “Active substance master files (ASMF).” EMA website. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/active-substance-master-files-asmf
[3] EMA. “Guidance for applicants submitting an ASMF for an active substance.” EMA website. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicants-submitting-active-substance-master-file-asmf_en.pdf
